Neurolief company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

neurolief.com

Founded Year

2014

Stage

Seed VC | Alive

About Neurolief

Neurolief creates a digital therapeutics platform of clinically proven neuromodulation-based solutions that can be delivered to patients at home or in the community.

Neurolief Headquarter Location

12 Giborei Israel

Yokneam, 4250412,

Israel

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Neurolief

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Neurolief is included in 4 Expert Collections, including Digital Health.

D

Digital Health

13,495 items

Companies developing and enabling evidence-based, software-driven therapeutic interventions to prevent, manage, or treat a medical disorder or disease. (*Scope follows the Digital Therapeutics Alliance definition)

M

Medical Devices

11,537 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

H

Health IT

7,900 items

Neurolief Patents

Neurolief has filed 7 patents.

The 3 most popular patent topics include:

  • Electrotherapy
  • Neurophysiology
  • Neurotechnology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/9/2017

10/26/2021

Electrotherapy, Neurotechnology, Neurophysiology, Neurological disorders, Neurotrauma

Grant

Application Date

4/9/2017

Grant Date

10/26/2021

Title

Related Topics

Electrotherapy, Neurotechnology, Neurophysiology, Neurological disorders, Neurotrauma

Status

Grant

Latest Neurolief News

Neurolief recruits first patient in Relivion DP system trial

Sep 24, 2021

The MOOD trial is designed to evaluate the safety and efficacy of Relivion DP as an adjunctive treatment to pharmaceutical management of MDD who have not achieved satisfactory improvement from antidepressant medications Relivion DP will help treat major depression by stimulating the release of neurotransmitters in the brainstem and modulating brain networks associated with mood control. (Credit: Business Wire) Neurotechnology company Neurolief has enrolled first patient in the clinical study to assess its brain neuromodulation system, dubbed Relivion DP, to treat major depressive disorder (MDD). The Relivion DP is claimed to be the first non-invasive and multi-channel brain neuromodulation system for at home treatment of neurological and neuropsychiatric disorders. The MOOD trial is designed to evaluate the safety and efficacy of Relivion DP as an adjunctive treatment to pharmaceutical management of MDD who have not achieved satisfactory improvement from antidepressant medications. Neurolief has recruited the first patient at Brown Department of Psychiatry and Human Behaviour in Butler Hospital located in Providence, Rhode Island. In a statement, the trial principal investigator Dr Linda Carpenter said: “The Relivion DP device offers a promising and convenient non-pharmacological solution with the potential to address the unmet needs of patients who do not respond to traditional therapies.” The latest trial is a prospective, multi-centre, two-arm, double-blind and randomised controlled trial that is followed by an open-label active treatment phase. The primary endpoint of the trial is said to evaluate changes in depressive symptoms from baseline to eight weeks post-treatment initiation when using Relivion DP, compared to the control group, in subjects suffering from MDD. Hamilton Rating Scale for Depression will assess the severity of depressive symptoms. Designed to worn as a headset, Relivion DP will help treat major depression by stimulating the release of neurotransmitters in the brainstem and modulating brain networks linked with mood control. With the support of three adaptive output channels, the device transfers mild electrical pulses to the brainstem through six branches of the occipital and trigeminal nerves. These nerves are used as conductors of the electrical stimulation to higher brain regions involved in mood, anxiety and attention disorders. The Relivion DP device, which is part of a disease management system, is used in tandem with its dedicated smartphone app and a cloud database to allow physicians to remotely monitor patient, analyse their data, and personalise treatments for better outcomes. In August last year, the company secured breakthrough device designation from the US Food and Drug Administration for Relivion DP device.

Neurolief Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Neurolief Rank

  • When was Neurolief founded?

    Neurolief was founded in 2014.

  • Where is Neurolief's headquarters?

    Neurolief's headquarters is located at 12 Giborei Israel, Yokneam.

  • What is Neurolief's latest funding round?

    Neurolief's latest funding round is Seed VC.

  • Who are the investors of Neurolief?

    Investors of Neurolief include Terra Venture Partners and Champel Capital.

  • Who are Neurolief's competitors?

    Competitors of Neurolief include Perfood and 5 more.

You May Also Like

Theranica Logo
Theranica

Theranica is a medical device company that aims to combine advanced neuromodulation therapy with modern wireless technology to develop proprietary electroceuticals that address prevalent medical conditions and diseases.

M-Sense Logo
M-Sense

M-sense provides a data-driven, mobile application for mapping out individual migraine patterns for the user. The app provides objective insights into migraine patterns, for instance, users can find out how weather, exercise, meditation, yoga, and other influential factors affect the frequency of migraines. M-sense collects all this data and can make it easily accessible to the user's doctor in order to assist the patient with relieving therapies.

E
Ease

Ease is a smartphone app for migraine and headache relief, is available without a prescription. The Ease app, developed by psychologists and headache specialists, addresses both the physical and psychological factors of migraine disease and tension-type headaches. Its content is based on scientifically-proven approaches with the aim of empowering users to self-manage their headaches. The app provides real-time biofeedback on their smartphone with physiological therapy, including mindfulness-based breathing exercises, to help patients build a healthier autonomic nervous system. Psychological support to manage stress, anxiety, and depression is provided with audio-based relaxation, meditation, and mindfulness exercises. A machine learning algorithm adjusts the user’s personalized support based on lifestyle and disease profile. The personalized guidance also provides the user with insights on any potential triggers (such as food, weather, and lifestyle factors) which might adversely impact their headache frequency and intensity.

P
Perfood

Perfood develops personalized, nutrition-based health applications for the digital therapy of diseases. The company serves customers operating in private sector organizations. It was founded in 2017 and is based in Lubeck, Germany.

B
Brainsgate

BrainsGate develops a technology for modulation of cerebro-vascular properties through neuro-stimulation of the spheno-palatine ganglion. Affected properties are central to many CNS disorders - blood vessel permeability and blood flow. Currently targeted applications include treatment of ischemic stroke and drug delivery to the CNS through modifying the permeability of the blood brain barrier. The Company has initiated clinical trials, delivering a chemotherapeutic agent to primary brain tumor patients.)

S
Salvia BioElectronics

Salvia BioElectronics is a start-up company that combines biology and electronics to provide effective therapeutic solutions through smart devices that use mild electrical impulses to influence nerve activity.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.